Ex-No­var­tis CEO Joe Jimenez is tak­ing an­oth­er crack at open­ing a new chap­ter in his ca­reer — and that in­cludes a new board seat and a $250M start­up

Joe Jimenez is back.

The ex-CEO of No­var­tis has tak­en a board seat on Cen­tu­ry Ther­a­peu­tics, the Ver­sant and Bay­er-backed start­up fo­cused on com­ing up with a brand new twist on cell ther­a­pies for can­cer — a field where Jimenez made his mark back­ing the first per­son­al­ized CAR-T ap­proved for use.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER